INDV

Indivior Pharmaceuticals, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001625297
$38.48 +0.92% $4.8B
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)17 New Institutional Positions
Vol
Market Cap$4.8B
Cap SizeMid Cap
Inst. Holders50 funds
Inst. Value$2.2B
Inst. Activity17 buys / 0 sells
Insider Activity3B / 2S
Insider Net $-$2.0M
SEC Reports9
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001625297·Prev Close $38.13

Recent Activity

Jun 12, 2026 SEC
Two senior insiders at Indivior (CFO and CSO) sold a combined $2.06M in open-market sales over a 4-day window. While the
CLUSTER — Impact 4/10
Jun 11, 2026 Insider
Heidbreder Christian sold 18,586 shares
Chief Scientific Officer @ $38.06 ($707.4K)
Jun 8, 2026 Insider
Preblick Ryan sold 36,000 shares
Chief Financial Officer @ $37.70 ($1.4M)
May 20, 2026 other
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
<p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV)
May 15, 2026 SEC
Indivior eliminated the Chief Scientific Officer position effective June 1, 2026, with Dr. Christian Heidbreder transiti
8-K — Impact 3/10
May 13, 2026 Insider
Wheadon David E. was granted 10,430 shares
Director
May 4, 2026 SEC
Indivior entered into a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 m
8-K — Impact 3/10
Inst.
BlackRock, Inc. — NEW
18,542,220 shares ($565.2M)

Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$51.50 (Jan 2026)
Current $38.48 Low $48.00 Median $50.00 High $59.00 6 analysts
$48.00 $59.00

Analyst Ratings

Historical distribution92% buy · 12 analysts · last covering-analyst action Jan 2026
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Jan 12, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.92 ▲ +22.7% $0.89 — $0.97 80% YoY 3
Next Q $0.99 ▲ +21.3% $0.96 — $1.03 38% YoY 3
Current FY $3.85 ▲ +23.1% $3.63 — $4.05 54% YoY 4
Next FY $3.92 ▲ +13.4% $3.10 — $4.27 2% YoY 5

Latest Reports

NEUTRAL CLUSTER 4/10
Two senior insiders at Indivior (CFO and CSO) sold a combined $2.06M in open-market sales over a 4-day window. While the
Jun 12, 2026
NEUTRAL 8-K 3/10
Indivior eliminated the Chief Scientific Officer position effective June 1, 2026, with Dr. Christian Heidbreder transiti
May 15, 2026
BULLISH Press 7/10
Indivior presented new real-world evidence at the ASAM Conference showing that its long-acting buprenorphine therapy SUB
Apr 24, 2026

Top Institutional Holders

FundValueMove
BlackRock, Inc.$565.2MNEW
VANGUARD PORTFOLIO MANAGEMENT LLC$240.5M—
VANGUARD CAPITAL MANAGEMENT LLC$170.3M—
STATE STREET CORP$149.5MNEW
FULLER & THALER ASSET$138.1MNEW

Recent Insider Trades

DateInsiderTypeValue
Jun 11, 2026Heidbreder ChristianSELL$707.4K
Jun 8, 2026Preblick RyanSELL$1.4M
May 13, 2026Wheadon DavidA$0.00
May 13, 2026NINIVAGGI DANIELA$0.00
May 13, 2026Ryan BarbaraA$0.00
50 institutional holders with $2.2B total value (73,311,130 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 17 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.18,542,220$565.2M25.3%NEW
2VANGUARD PORTFOLIO MANAGEMENT LLC7,891,819$240.5M10.8%—
3VANGUARD CAPITAL MANAGEMENT LLC5,586,576$170.3M7.6%—
4STATE STREET CORP4,903,993$149.5M6.7%NEW
5FULLER & THALER ASSET MANAGEMENT, INC.4,529,583$138.1M6.2%NEW
6CITADEL ADVISORS LLC3,574,044$108.9M4.9%—
7MORGAN STANLEY3,505,817$106.9M4.8%NEW
8GOLDMAN SACHS GROUP INC2,409,165$73.4M3.3%—
9ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2,323,264$70.8M3.2%NEW
10DRIEHAUS CAPITAL MANAGEMENT LLC1,880,039$57.3M2.6%NEW
11HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND1,835,100$55.9M2.5%NEW
12BARCLAYS PLC1,745,751$53.2M2.4%—
13Invesco Ltd.1,561,763$47.6M2.1%NEW
14DIMENSIONAL FUND ADVISORS LP1,332,128$40.6M1.8%NEW
15FEDERATED HERMES, INC.1,217,721$37.1M1.7%NEW
16CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,141,885$34.8M1.6%NEW
17Nuveen, LLC930,911$28.4M1.3%NEW
18VANGUARD FIDUCIARY TRUST CO858,176$26.2M1.2%—
19BANK OF AMERICA CORP /DE/667,132$20.3M0.9%NEW
20Rubric Capital Management LP662,515$20.2M0.9%NEW

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BlackRock, Inc.NEW—18,542,220—$565.2M2026-Q1
STATE STREET CORPNEW—4,903,993—$149.5M2026-Q1
FULLER & THALER ASSET MANAGEMENT, INC.NEW—4,529,583—$138.1M2026-Q1
MORGAN STANLEYNEW—3,505,817—$106.9M2026-Q1
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW—2,323,264—$70.8M2026-Q1
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDNEW—1,835,100—$55.9M2026-Q1
Invesco Ltd.NEW—1,561,763—$47.6M2026-Q1
DIMENSIONAL FUND ADVISORS LPNEW—1,332,128—$40.6M2026-Q1
FEDERATED HERMES, INC.NEW—1,217,721—$37.1M2026-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW—1,141,885—$34.8M2026-Q1
Nuveen, LLCNEW—930,911—$28.4M2026-Q1
BANK OF AMERICA CORP /DE/NEW—667,132—$20.3M2026-Q1
Rubric Capital Management LPNEW—662,515—$20.2M2026-Q1
FMR LLCNEW—527,714—$16.1M2026-Q1
PUBLIC SECTOR PENSION INVESTMENT BOARDNEW—446,636—$13.6M2026-Q1
Hudson Bay Capital Management LPNEW—364,212—$11.1M2026-Q1
RHUMBLINE ADVISERSNEW—333,331—$10.2M2026-Q1
DRIEHAUS CAPITAL MANAGEMENT LLCNEW—2,000,339—$71.8M2025-Q4
12 unique insiders with 33 transactions. Net insider value: -$2.0M ($31.2K bought, $2.1M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 11, 2026Heidbreder ChristianChief Scientific OfficerSELL18,586$38.06$707.4K
Jun 8, 2026Preblick RyanChief Financial OfficerSELL36,000$37.70$1.4M
May 13, 2026Wheadon David E.DirectorAWARD10,430——
May 13, 2026NINIVAGGI DANIEL ADirectorAWARD6,518——
May 13, 2026Ryan BarbaraDirectorAWARD6,518——
May 13, 2026Kingsley Stuart ADirectorAWARD6,518——
May 13, 2026Humphreys KeithDirectorAWARD6,518——
May 13, 2026Thompson JulietDirectorAWARD6,518——
May 12, 2026Thompson JulietDirectorTAX W/H1,117$38.28$42.8K
Mar 14, 2026Preblick RyanChief Financial OfficerTAX W/H2,843$31.11$88.4K
Mar 14, 2026Preblick RyanChief Financial OfficerEXERCISE6,302——
Mar 13, 2026Ryan BarbaraDirectorBUY8$31.09$248.68
Mar 9, 2026Ryan BarbaraDirectorBUY31$32.56$1.0K
Mar 6, 2026Kingsley Stuart ADirectorBUY940$31.87$30.0K
Mar 3, 2026Preblick RyanChief Financial OfficerEXERCISE113,510——
Mar 3, 2026Heidbreder ChristianChief Scientific OfficerEXERCISE132,565——
Mar 3, 2026Anderson Woodrow DChief Accounting OfficerEXERCISE23,975——
Mar 3, 2026Anderson Woodrow DChief Accounting OfficerEXERCISE5,946——
Mar 3, 2026Anderson Woodrow DChief Accounting OfficerEXERCISE18,364——
Mar 3, 2026Burris Jeffrey WChief Legal OfficerEXERCISE79,893——
Mar 3, 2026Burris Jeffrey WChief Legal OfficerEXERCISE104,300——
Mar 3, 2026Heidbreder ChristianChief Scientific OfficerEXERCISE101,544——
Mar 3, 2026Preblick RyanChief Financial OfficerTAX W/H87,597$31.98$2.8M
Feb 10, 2026Anderson Woodrow DChief Accounting OfficerAWARD6,903——
Feb 10, 2026Preblick RyanChief Financial OfficerAWARD37,358——
Feb 10, 2026Burris Jeffrey WChief Legal OfficerAWARD26,897——
Feb 10, 2026Heidbreder ChristianChief Scientific OfficerAWARD33,622——
Feb 10, 2026Barry Patrick AChief Commercial OfficerAWARD31,380——
Feb 10, 2026Ciaffoni JosephChief Executive OfficerAWARD79,976——
Feb 9, 2026Anderson Woodrow DChief Accounting OfficerAWARD23,975——
Feb 9, 2026Preblick RyanChief Financial OfficerAWARD113,510——
Feb 9, 2026Burris Jeffrey WChief Legal OfficerAWARD104,300——
Feb 9, 2026Heidbreder ChristianChief Scientific OfficerAWARD132,565——
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 4.1/10.
NEUTRAL CLUSTER 4/10
Two senior insiders at Indivior (CFO and CSO) sold a combined $2.06M in open-market sales over a 4-d
Jun 12, 2026
NEUTRAL 8-K 3/10
Indivior eliminated the Chief Scientific Officer position effective June 1, 2026, with Dr. Christian
May 15, 2026
NEUTRAL 8-K 3/10
Indivior entered into a $175 million accelerated share repurchase agreement with Barclays as part of
May 4, 2026
BULLISH 8-K 8/10
Indivior reported Q1 2026 results with total net revenue of $317M (+19% YoY) and GAAP diluted EPS of
Apr 30, 2026
NEUTRAL PRESS-RELEASE 3/10
Indivior announced its upcoming Q1 2026 earnings release scheduled for April 30, 2026, with no finan
Apr 9, 2026
NEUTRAL CLUSTER 2/10
Director Ryan Barbara made two small open-market purchases of INDV stock totaling approximately $1,2
Mar 13, 2026
NEUTRAL 8-K 3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 13, 2026
NEUTRAL 8-K 3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 12, 2026
BULLISH 8-K 8/10
Indivior reported strong 2025 financial results with record SUBLOCADE net revenue of $856 million (u
Feb 26, 2026
BULLISH 7/10
Indivior presented new real-world evidence at the ASAM Conference showing that its long-acting bupre
Apr 24, 2026
MIXED 6/10
Indivior Pharmaceuticals announced the pricing of a $450 million offering of 0.625% convertible seni
Mar 13, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 92% buy across 12 analysts — 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$51.50 mean target (Jan 2026)
$48.00 Low $59.00 High
MetricValue
Current Price$38.48
Target Low$48.00
Target Mean$51.50
Target Median$50.00
Target High$59.00
# Analysts6
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.92 $0.89 $0.97 80.4% +22.7% 2↑ 0↓ $0.3B 1.5% 3
Next Q
2026-09-30
 $0.99 $0.96 $1.03 37.5% +21.3% 1↑ 1↓ $0.3B 0.2% 3
Current FY
2026-12-31
 $3.85 $3.63 $4.05 54.1% +23.1% 4↑ 0↓ $1.3B 1.5% 4
Next FY
2027-12-31
 $3.92 $3.10 $4.27 1.8% +13.4% 4↑ 0↓ $1.3B 2.3% 5

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.920
7d ago$0.920
30d ago$0.750+0.170
60d ago$0.746+0.174
90d ago$0.724+0.196
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jan 12, 2026 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264710092%
May 1, 20264710092%
Apr 1, 20264810092%
Mar 1, 20264810092%
Feb 1, 20264810092%
Jan 1, 20264810092%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 20, 2026
other
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
<p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world e
May 20, 2026
short_volume
Short Volume: INDV — 56.6% short (0.7M / 1.3M)
Short: 746,397 | Exempt: 1 | TRF Vol: 1,319,296 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: INDV — 56.0% short (0.4M / 0.7M)
Short: 391,786 | Exempt: 785 | TRF Vol: 699,931 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: INDV — 57.0% short (0.3M / 0.6M)
Short: 343,373 | Exempt: 0 | TRF Vol: 602,626 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_interest
FTD: INDV — 29,735 shares ($1.2M) failed to deliver
Settlement: 20260512, Price: $38.84, FTD Value: $1,154,907.4, INDIVIOR PHARMACEUTICALS INC C
May 7, 2026
short_volume
Short Volume: INDV — 59.6% short (0.5M / 0.8M)
Short: 477,944 | Exempt: 0 | TRF Vol: 802,162 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
<p>RICHMOND, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the firs
Apr 30, 2026
earnings_calendar
INDV Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
short_volume
Short Volume: INDV — 68.0% short (0.5M / 0.7M)
Short: 462,450 | Exempt: 0 | TRF Vol: 679,600 | Short Ratio: 68.0% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: INDV — 60.1% short (0.4M / 0.6M)
Short: 365,520 | Exempt: 0 | TRF Vol: 608,555 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
fda
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
<p>RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder
Apr 23, 2026
earnings_calendar
INDV Q1 2026 Earnings Scheduled — 2026-04-23
Apr 22, 2026
short_volume
Short Volume: INDV — 58.0% short (0.4M / 0.6M)
Short: 369,276 | Exempt: 0 | TRF Vol: 637,072 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
other
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
<p align="left">RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a <a href="https://www.gl
Apr 14, 2026
short_volume
Short Volume: INDV — 57.6% short (0.3M / 0.5M)
Short: 315,156 | Exempt: 0 | TRF Vol: 547,153 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
INDV-6001 Multiple-Dose Pharmacokinetic Study
Phase Phase 2 — COMPLETED